Aug. 7 at 8:32 PM
$CMPS anyone who doesn’t think this is undervalued I would be curious to hear your reasoning.
$CMPS has been the leader in this sector since MAPS was rejected. And on top of that their COMP360 is being used in tons of trials outside of just their own, proving results. Plus being the leader, working with the VA (FDA will love), EO and the priority voucher to give them an extra min 10 month head start on what that already had vs everyone else. I hear the small target population argument too much, by the time others are approved and reclassified, clinics and providers will be comfortable with the medicine and be off labeling for MDD and seeing results, why would they opt for something equally as taxing on the clinic if they are already comfortable. I do think there is room for all these medicines and feel the first to market is being underestimated.
